Canadian biotech advances RESOLVE Phase 2b trial for gastrointestinal indications with topline data expected H2 2026
Eupraxia Pharmaceuticals announced Q2 results and achieved a significant clinical milestone with first patient dosing in its RESOLVE Phase 2b trial evaluating EP-104GI for gastrointestinal indications.
The RESOLVE trial represents a key value driver for Eupraxia’s DiffuSphere technology platform, which enables extended-release formulations of established drugs to improve patient outcomes and compliance.
Development Timeline: With first patient dosing completed, Eupraxia expects topline data from the RESOLVE trial in the second half of 2026, providing sufficient time for robust enrollment and data collection in this patient population.
EP-104GI leverages Eupraxia’s proprietary microsphere technology to deliver sustained drug release, potentially reducing dosing frequency and improving therapeutic outcomes compared to existing treatments. The gastrointestinal indication represents a significant commercial opportunity given the prevalence of GI disorders and need for improved treatment options.
Platform Validation: Success in the RESOLVE trial could validate Eupraxia’s DiffuSphere platform for multiple applications, supporting the company’s pipeline of extended-release formulations across various therapeutic areas.
The Phase 2b design provides the opportunity to demonstrate both efficacy and safety while generating data to support potential partnerships or licensing opportunities in the competitive GI therapeutics market.
